Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Ursula von der Leyen

- PMLiVE

Alnylam’s Amvuttra granted EC approval to treat rare heart disease ATTR-CM

The RNAi therapeutic has been authorised to treat both wild type and hereditary forms of the disease

- PMLiVE

AstraZeneca’s Calquence approved by EC for first-line chronic lymphocytic leukaemia use

An estimated 27,000 cases of the disease were diagnosed in the UK, France, Germany, Spain and Italy in 2024

- PMLiVE

Takeda receives EC approval for Adcetris combination in Hodgkin lymphoma

The decision marks the second approval for an Adcetris-based regimen for front-line Hodgkin lymphoma

- PMLiVE

BeiGene’s Tevimbra combination granted EC approval in small cell lung cancer

Approximately 15% of all lung cancer patients are diagnosed with the aggressive disease

regeneron headquarters

Regeneron’s bispecific antibody Lynozyfic approved by EC to treat multiple myeloma

More than 35,000 new cases of the blood cancer are diagnosed in Europe every year

Biogen Idec building

Biogen/Eisai’s Alzheimer’s disease drug Leqembi granted EC approval

The neurodegenerative disorder currently affects an estimated 6.9 million people in Europe

- PMLiVE

J&J’s subcutaneous Darzalex regimen approved by EC for newly diagnosed multiple myeloma

More than 35,000 people in the EU were diagnosed with the blood cancer in 2022

- PMLiVE

Roche’s Columvi granted EC approval to treat diffuse large B-cell lymphoma

Approximately 38,000 people are diagnosed with DLBCL every year in Europe

- PMLiVE

Johnson & Johnson’s subcutaneous Rybrevant granted EC approval to treat NSCLC

It is hoped that the formulation will improve the treatment experience for patients

- PMLiVE

AbbVie’s Rinvoq receives EC approval to treat adults with giant cell arteritis

The drug is now the first oral JAK inhibitor to be approved in the EU for this patient population

- PMLiVE

AstraZeneca’s Imfinzi regimen receives EC approval to treat resectable NSCLC

More than 450,000 people are diagnosed with lung cancer every year in Europe

- PMLiVE

J&J’s Stelara granted EC approval to treat Crohn’s disease in paediatric patients

Approximately 25% of cases are diagnosed during childhood or adolescence

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links